AstraZeneca PLC
10468.00
07-May-25 11:29:57
15 minutes delayed
Stocks
-256.00
-2.39%
Today's range
10392.00 - 10552.00
ISIN
N/A
Source
Cboe
-
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
28 Jun 2024 10:33:02 By NASDAQ Stocks
-
AstraZeneca: Imfinzi Trial Fails To Meet Endpoint In Early-stage Non-small Cell Lung Cancer
25 Jun 2024 03:08:02 By NASDAQ US Markets
-
AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer
18 Jun 2024 03:15:21 By NASDAQ US Markets
-
AstraZeneca's Calquence Combo Cuts Progression Risk By 27% In Mantle Cell Lymphoma Trial
16 Jun 2024 12:33:03 By NASDAQ US Markets
-
FDA Approves AstraZeneca's Farxiga For Pediatric Use In Type-2 Diabetes
12 Jun 2024 21:53:19 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
10 Jun 2024 03:21:31 By NetDania Notify
-
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs
07 Jun 2024 12:13:02 By NASDAQ Stocks
-
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
05 Jun 2024 19:29:29 By Forbes - World
-
AstraZeneca Completes Acquisition Of Fusion Pharma
05 Jun 2024 03:08:45 By NASDAQ US Markets
-
CHMP Recommends Approval Of AstraZeneca's Tagrisso Combo For EGFR-Mutated Advanced Lung Cancer
03 Jun 2024 03:15:45 By NASDAQ US Markets
-
Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris
30 May 2024 05:59:20 By NASDAQ US Markets
-
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
29 May 2024 10:20:48 By NASDAQ US Markets
-
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
29 May 2024 08:32:19 By NASDAQ US Markets
-
AZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical Significance
27 May 2024 02:59:14 By NASDAQ US Markets
-
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
24 May 2024 10:30:58 By NASDAQ Stocks
-
NetDania - New 12 months High: AstraZeneca PLC
23 May 2024 10:35:27 By NetDania Notify
-
AstraZeneca Targets $80 Bln Revenue By 2030, Plans To Launch 20 New Medicines
21 May 2024 03:02:29 By NASDAQ US Markets
-
AstraZeneca To Build $1.5 Bln Manufacturing Facility In Singapore For Antibody Drug Conjugates
20 May 2024 02:42:36 By NASDAQ US Markets
-
AstraZeneca: New Data Shows Tezspire's Role In Future COPD Treatment
19 May 2024 22:05:22 By NASDAQ US Markets
-
AZN:Phase III Trial Of Sipavibart Met Main Goal In Preventing COVID-19 In Immunocompromised Patients
16 May 2024 03:51:29 By NASDAQ US Markets